This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Gracell Biotechnologies (Shanghai) Co., Ltd., Suzhou Gracell Biotechnologies Co., Ltd.. Active years: 2025.
Company Filing History:
1 out of 4 
1 out of 1 Years Active: 2025
Title: Shuyi Qiu: Innovator in T Cell Engineering
Introduction
Shuyi Qiu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of immunology, particularly in T cell engineering. His innovative work focuses on enhancing the effectiveness of immune cells in targeting tumors.
Latest Patents
Shuyi Qiu holds a patent for "Compositions and methods for T cell engineering." This patent describes an engineered immune cell that includes a CAR (Chimeric Antigen Receptor) or engineered TCR (T Cell Receptor). The engineered immune cells are designed to inhibit host immune cells, such as T cells and NK cells, while enhancing their own survival and persistence in vivo. This advancement allows for more effective tumor-killing activity.
Career Highlights
Throughout his career, Shuyi Qiu has worked with notable companies in the biotechnology sector. He has been associated with Gracell Biotechnologies (Shanghai) Co., Ltd. and Suzhou Gracell Biotechnologies Co., Ltd. His work in these organizations has contributed to the development of innovative therapies in cancer treatment.
Collaborations
Shuyi Qiu has collaborated with several professionals in his field, including Xinxin Wang and Tao Jin. These collaborations have fostered a productive environment for research and development in T cell engineering.
Conclusion
Shuyi Qiu's contributions to T cell engineering represent a significant advancement in immunotherapy. His innovative approaches and patented technologies hold promise for improving cancer treatment outcomes.